HC Wainwright & Co. : Indaptus Therapeutics (INDP.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $12.00.

HC Wainwright & Co. : Indaptus Therapeutics (INDP.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $12.00.

Zhitong FinanceApr 15 18:11

HC Wainwright & Co. Reiterates Buy on Indaptus Therapeutics, Maintains $12 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Indaptus Therapeutics (NASDAQ:INDP) with a Buy and maintains $12 price target.

BenzingaApr 15 18:08

Indaptus Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/15/2024 322.54% HC Wainwright & Co. → $12 Reiterates Buy → Buy 09/20/2023 322.54% HC Wainwright & Co. →

BenzingaApr 15 18:06

Buy Rating for Indaptus Therapeutics: Promising Oncology Breakthrough With Decoy20 Platform

TipRanksApr 13 03:05

Indaptus Therapeutics Unveils Details On Mechanism Of Action Data That Demonstrates The Company's Decoy Platform Induces, Matures Or Activates Multiple Immune Cell Types Involved In Anti-tumor Responses, At AACR Research Annual Meeting

Indaptus Therapeutics Unveils Details On Mechanism Of Action Data That Demonstrates The Company's Decoy Platform Induces, Matures Or Activates Multiple Immune Cell Types Involved In Anti-tumor Respons

BenzingaApr 11 19:35

12 Health Care Stocks Moving In Friday's Pre-Market Session

GainersProtara Therapeutics (NASDAQ:TARA) stock increased by 40.3% to $5.64 during Friday's pre-market session. The market value of their outstanding shares is at $64.4 million. Candel Therapeutics (N

BenzingaApr 5 20:09